bioAffinity Technologies, Inc. announced on May 20, 2025, the appointment of Gordon Downie, M.D., Ph.D., as its Chief Medical Officer. Dr. Downie is a pulmonologist and serves as the Director of Clinical Research at Pulmonary and Allergy Associates and Clinical Professor of Medicine at the University of Medicine and Dentistry of New Jersey-Rutgers.
Dr. Downie brings extensive expertise in pulmonary medicine and lung cancer screening, having participated in over 180 clinical studies and authored more than 260 publications. His experience will be instrumental in guiding bioAffinity's scientific and clinical strategies.
This key executive appointment is expected to shape the company's clinical direction, including the advancement of its pivotal clinical trials for CyPath® Lung and the development of companion diagnostics for other lung diseases like asthma and COPD.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.